STOCK TITAN

Metagenomi - MGX STOCK NEWS

Welcome to our dedicated page for Metagenomi news (Ticker: MGX), a resource for investors and traders seeking the latest updates and insights on Metagenomi stock.

Metagenomi Inc (MGX) is a clinical-stage biotechnology company pioneering next-generation gene editing systems derived from metagenomic discovery. This news hub provides investors and researchers with essential updates on therapeutic developments, strategic partnerships, and scientific advancements in precision genetic medicines.

Access real-time announcements covering MGX's evolving pipeline, including progress in hemophilia A therapies and novel editing tools like ultra-small base editors. The curated collection features press releases on preclinical milestones, financial reports, and collaborations advancing in vivo delivery systems for genetic disorders.

Key updates include regulatory filings, peer-reviewed research publications, and conference presentations demonstrating the company's metagenomics-powered platform. Track developments in AI-optimized enzyme design and therapeutic programs targeting previously inaccessible genetic mutations.

Bookmark this page for verified updates on MGX's progress in developing durable, single-dose therapies. Regularly refreshed content ensures stakeholders maintain informed perspectives on this innovator's role in expanding the boundaries of genome editing.

Rhea-AI Summary

Metagenomi (Nasdaq: MGX) reported its full year 2024 financial results and business updates. The company ended Q4 2024 with $248.3 million in cash and equivalents, providing runway into 2027. Key highlights include sustained Factor VIII activity in nonhuman primate study for hemophilia A program for over 16 months, and advancement of four Wave 1 Ionis targets to lead optimization.

Financial results show R&D expenses increased to $109.2 million in 2024 from $94.4 million in 2023, while G&A expenses rose to $32.0 million from $28.8 million. The company's pipeline achievements include declaring development candidate MGX-001 for hemophilia A, achieving in vivo proof-of-concept across three secreted protein targets, and demonstrating 95% protein knockdown in hypertension studies.

Looking ahead, Metagenomi plans to release final FVIII durability data in H1 2025, file IND submissions in 2026, and nominate 1-2 development candidates from Ionis collaboration programs in 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.98%
Tags
-
Rhea-AI Summary

Metagenomi (Nasdaq: MGX) has published groundbreaking research in Nature Communications showcasing its novel, compact CRISPR-associated transposase (CAST) system for large gene integration. The company's AI-driven metagenomics platform discovered a compact Cas12k CAST system capable of precisely integrating therapeutic genes into the human genome.

Key achievements include:

  • Successfully integrated large, therapeutically relevant genes into human cells
  • Developed a first-in-class 'all-in-one' mRNA delivery approach
  • Demonstrated integration of multiple cargoes to a safe-harbor site in the human genome

This technology shows potential for treating complex genetic diseases such as Wilson's disease, cystic fibrosis, and Duchenne Muscular Dystrophy. The company expects additional advancements in their large gene integration technology in 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.83%
Tags
none
-
Rhea-AI Summary

Metagenomi (Nasdaq: MGX), a precision genetic medicines company, has announced that CEO and founder Brian C. Thomas, PhD, will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference on March 5, 2025, from 1:10-1:40 p.m. ET in Boston. The company will also host one-on-one investor meetings during the conference.

Metagenomi leverages an AI-driven metagenomics platform to develop curative therapeutics. The company's comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems. By studying genetic material from natural environments, Metagenomi has unlocked four billion years of microbial evolution to discover novel editing tools capable of correcting genetic mutations throughout the genome.

A live webcast of the presentation will be available on the company's investor relations website, with a replay available for a time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.17%
Tags
conferences
Rhea-AI Summary

Metagenomi (Nasdaq: MGX) has provided updates on its therapeutic development programs and outlined key milestones for 2025-2026. The company reported significant progress in its MGX-001 hemophilia A program, achieving sustained Factor VIII activity in nonhuman primate studies over 16+ months. The company plans regulatory interactions in 2025 and IND/CTA submissions in 2026.

The company is advancing its secreted protein deficiencies program, expecting NHP proof-of-concept in 2025 and development candidate nomination in 2026. In collaboration with Ionis, Metagenomi is progressing on cardiometabolic programs, targeting one to two development candidate nominations in 2025.

Metagenomi has also advanced its technology platforms, including compact SMART nucleases and novel Adenine Base Editors. The company's cash runway is expected to support operations into 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
none
-
Rhea-AI Summary

Metagenomi (Nasdaq: MGX) has announced the appointment of Eric Bjerkholt, MBA, to its Board of Directors, effective January 27, 2025. Bjerkholt, currently CFO of Mirum Pharmaceuticals, will serve on Metagenomi's Audit and Compensation committees.

Bjerkholt brings significant pharmaceutical industry experience, having served as CFO at several companies including Chinook Therapeutics (acquired by Novartis AG) and Aimmune Therapeutics (acquired by Nestle Health Science). At Sunesis Pharmaceuticals, he held multiple executive roles including Executive VP of Corporate Development and Finance. His background includes healthcare investment banking at J.P. Morgan and senior finance roles at various companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
management
-
Rhea-AI Summary

Metagenomi (Nasdaq: MGX), a precision genetic medicines company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO and founder, Brian C. Thomas, PhD, will deliver a presentation on Wednesday, January 15, 2025, at 4:30 p.m. PT in San Francisco.

The presentation will be accessible through a live webcast on the investor section of Metagenomi's website at https://ir.metagenomi.co/. A replay option will be available for a time at the same web address. Metagenomi specializes in developing curative therapeutics using its proprietary gene editing toolbox.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
conferences
Rhea-AI Summary

Metagenomi (Nasdaq: MGX) presented data demonstrating the precision and safety of its gene editing tools at the Nature Conference: RNA at the Bench and Bedside IV. The company highlighted two key developments: MGX-001, their hemophilia A candidate using the MG29-1 nuclease, showed no identifiable off-target editing and no evidence of translocations in primary human hepatocytes. Additionally, their Adenine Base Editor (ABE) for ex vivo cell therapy demonstrated no detectable translocations and no significant genomic base composition differences in primary T-cells compared to unedited cells.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags
none
-
Rhea-AI Summary

Metagenomi (MGX) presented updated preclinical data for its hemophilia A program at the ASH 66th Annual Meeting. The company's gene editing approach demonstrated sustained Factor VIII (FVIII) activity levels through more than 16 months in nonhuman primates (NHPs). The study involved three NHPs receiving a single treatment, showing FVIII activity maintenance at 72%, 9%, and 30% at the 16.5-month timepoint.

The company's lead candidate, MGX-001, which uses a B-domain deleted bioengineered FVIII construct, achieved higher FVIII activity compared to wild type FVIII at similar integration rates. The program is on track for IND filing in 2026. The treatment showed only transient elevation of liver transaminases with no other safety concerns, positioning it as a potential one-time curative treatment for both adults and children with hemophilia A.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
-
Rhea-AI Summary

Metagenomi (MGX) reported Q3 2024 financial results and business updates, highlighting the nomination of MGX-001, their first development candidate for hemophilia A treatment. The company demonstrated successful proof-of-concept with durable Factor VIII activity levels over 12 months in nonhuman primates. Financial highlights include $274.6 million in cash and equivalents, with runway into 2027. R&D expenses were $26.3 million and G&A expenses were $7.6 million. The company expects one to two development candidate nominations in 2025 from their Ionis collaboration programs focusing on cardiometabolic indications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.9%
Tags
Rhea-AI Summary

Metagenomi (Nasdaq: MGX) announced that its abstract on Factor VIII gene insertion has been accepted for oral presentation at the American Society of Hematology (ASH) 66th Annual Meeting in December 2024. The presentation will showcase preclinical proof-of-concept data for their lead candidate MGX-001, which aims to provide a single, curative treatment for hemophilia A.

The research demonstrates durable Factor VIII expression in nonhuman primates, addressing current therapy limitations that fail to prevent breakthrough bleeding. The presentation, led by VP Preclinical Alan Brooks, PhD, is scheduled for December 9, 2024, at 5:30 PM in San Diego Convention Center.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
conferences
Metagenomi

Nasdaq:MGX

MGX Rankings

MGX Stock Data

56.82M
26.75M
28.83%
28.77%
7.09%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
EMERYVILLE